Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares

Ghiath Sukhtian, a director and 10% owner of Outlook Therapeutics, boosted his ownership in the company by purchasing $2.5 million worth of shares and warrants on August 12, 2026. Sukhtian, through his entity GMS Ventures, bought 2,525,252 shares at $0.99 per share, while also acquiring 2,525,252 warrants to purchase additional shares at $1.1 per share, with no separate payment required.

The warrants, exercisable immediately upon issuance, were set to expire on August 14, 2031. Sukhtian, who holds a controlling interest in GMS Ventures, is considered a director by deputization, with two representatives on the Issuer’s board. Despite recent market volatility leading to the stock trading at $0.76, which is below its purchase price, the acquisition is seen as undervalued by AI analysis.

Outlook Therapeutics reported a narrowed fiscal third-quarter loss, launching its newly approved eye drug LYTENAVA in the U.S., which has been approved by the FDA.